Spyre Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $1,042 |
Gross Profit | 78 | |||
EBITDA | -55,392 | -44,147 | -47,774 | -47,754 |
EBIT | -47,817 | -47,534 | ||
Net Income | -69,028 | -38,837 | -43,857 | -63,180 |
Net Change In Cash | 0 | 0 | 0 | 1,042 |
Free Cash Flow | -29,421 | -62,248 | -28,542 | -31,036 |
Cash | 71,580 | 45,144 | 227,552 | 188,893 |
Basic Shares | 50,889 | 45,316 | 36,512 | 5,595 |
Annual Financials
| Values in thousands | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
Revenue | $886 | $886 | $2,329 | $18,739 |
Gross Profit | -78 | -78 | 365 | 16,738 |
EBITDA | -127,820 | -242,303 | -83,214 | -63,659 |
EBIT | -128,784 | -243,047 | -85,178 | -65,660 |
Net Income | -338,790 | -338,790 | -83,815 | -65,801 |
Net Change In Cash | 886 | 886 | 2,329 | 18,739 |
Free Cash Flow | -99,910 | -99,910 | -80,182 | -54,289 |
Cash | 188,893 | 188,893 | 34,863 | 15,142 |
Basic Shares | 6,897 | 6,897 | 3,371 | 2,629 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$1.36 |
2024-06-30 | -$0.86 |
2024-03-31 | -$1.20 |
2023-12-31 | -$4.05 |
